Screening Library definition

Screening Library means the Xxxxx Compound Library or the Tularik Compound Library.
Sample 1Sample 2
Screening Library shall have the meaning given in the first recital. [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.
Sample 1Sample 2
Screening Library means a chemical compound library, other than a Focused Library, comprising at least 108 distinct target structures, based on specific agreed scaffold(s) and synthons, prepared by DiCE for use in DiCE internal and external programs, including the Research Program.
Sample 1

Examples of Screening Library in a sentence

  • The Roche Bioscience Screening Library is not part of the Research Compound Library, but may, in Roche Bioscience's sole discretion, be used in HTS against the Targets.

  • The Roche Bioscience Screening Library shall be treated as Roche Bioscience's Confidential Information.

  • Title to and ownership of all Inventions directly related to the NeoMorph Screening Library, ALIS screening technology or QSCD (regardless of inventorship), as well as those Inventions subject to Section 3.5(b)(i) (hereinafter "NEOGENESIS INVENTIONS"), shall be the sole property of NeoGenesis and are included in NeoGenesis Know-How and/or NeoGenesis Patent Rights, as the case may be.

  • Patents and under Tularik's interest in any Joint Patents (and if the Product is from the Tularik Screening Library, any other Tularik Patent Rights claiming such Library Compound) to develop, make, have made, use, offer to sell, sell or import Products incorporating Roche Bioscience Compounds for the treatment of Roche Bioscience Indications during the term of this Agreement.

  • Except for the Roche Bioscience Screening License, Tularik shall have no rights to compounds originating from the Roche Bioscience Screening Library unless a Library Compound becomes a Development Compound under Section 5.2. Roche Bioscience shall provide structural information on Validated Hits[ * ].

  • The penultimate sentence of Section 5.6 of the Agreement is hereby amended to read as follows: Derivatives made as part of a Collaboration Medicinal Chemistry Program from compounds originating from the Tularik Screening Library shall be considered part of the Research Compound Library.

  • Except for the Tularik Screening License, Roche Bioscience shall have no rights to compounds originating from the Tularik Screening Library unless a Library Compound becomes a Development Compound under Section 5.2. Tularik shall provide structural information to Roche Bioscience on Validated Hits [ * ].

  • Derivatives made as a result of HTS as part of the Research Collaboration from compounds originating from the Tularik Screening Library shall be considered part of the Research Compound Library.

  • Derivatives made as part of a Collaboration Medicinal Chemistry Program from compounds originating from the Roche Bioscience Screening Library shall be considered part of the Roche Compound Library.

  • Figure 3.2: Overview of Bond Issuance Methods in the Republic of Korea Source: Korea Financial Investment Association.

Related to Screening Library

  • Screening Test means a drug or alcohol test which uses a method of analysis allowed by the Minnesota Drug and Alcohol Testing in the Workplace Act to be used for such purposes.

  • Screening Test Technician (STT) means anyone who instructs and assists individuals in the alcohol testing process and operates an ASD.

  • Library means an organized collection of resources made accessible to the public for reference or borrowing supported with money derived from taxation.

  • Screening means the evaluation process used to identify an individual's ability to perform activities of daily living and address health and safety concerns.

  • Alcohol Screening Device (ASD) means a breath or saliva device, other than an Evidential Breath Testing Device (EBT), that is approved by the National Highway Traffic Safety Administration and placed on its Conforming Products List for such devices.

  • Assay means a laboratory analysis of Crude Petroleum to include the following: A.P.I. Gravity, Reid vapor pressure, composition, pour point, water and sediment content, sulfur content, viscosity, distillation, hydrogen sulfide, flash/boiling point and other characteristics as may be required by Carrier.

  • Fluoroscopic imaging assembly means a subsystem in which X-ray photons produce a visual image. It includes the image receptor(s) such as the image intensifier and spot-film device, electrical interlocks, if any, and structural material providing linkage between the image receptor and diagnostic source assembly.

  • Phase I Trial means a Clinical Trial, the principal purpose of which is preliminary determination of safety of an investigational product in healthy individuals or patients or that otherwise meets the requirements described in 21 C.F.R. §312.21(a), or similar Clinical Trial in a country other than the United States.

  • Biological Samples means any physical samples obtained from Study Participants in accordance with the Protocol for the purposes of the Study.

  • Phase I Clinical Study means a human clinical study of a product, the principal purpose of which is a preliminary determination of safety in healthy individuals or patients, as described in 21 C.F.R. 312.21(a).

  • Phase I Clinical Trial means a human clinical trial that is intended to initially evaluate the safety and/or pharmacological effect of a Product in subjects or that would otherwise satisfy requirements of 21 C.F.R. 312.21(a), or its foreign equivalent.

  • Study means the investigation to be conducted in accordance with the Protocol.

  • Biomarker means a parameter or characteristic in a patient or Patient Sample, the measurement of which is useful (a) for purposes of selecting appropriate therapies or patient populations or monitoring disease susceptibility, severity or state, or monitoring therapies for such patient and/or (b) for predicting the outcome of a particular treatment of such patient.

  • Development Site means any parcel or lot on which exists or which is intended for building development other than the following:

  • Collaboration Compound means any of the following: (a) FG-4592, (b) any HIF Compound (other than FG-4592) that is added to this Agreement pursuant to Section 3.6, and (c) any salts, esters, complexes, chelates, crystalline and amorphous morphic forms, pegylated forms, enantiomers (excluding regioisomers), prodrugs, solvates, metabolites and catabolites of any of the foregoing ((a) or (b)).

  • Step therapy protocol means a protocol or program that establishes the specific

  • Healing arts screening means the testing of human beings using x-ray machines for the detection or evaluation of health indications when such tests are not specifically and individually ordered by a licensed practitioner of the healing arts legally authorized to prescribe such x-ray tests for the purpose of diagnosis or treatment.

  • Phase II Clinical Study means a human clinical study of a product initiated to determine the safety and efficacy in the target patient population, as described 21 C.F.R. 312.21(b).

  • Phase IIb Clinical Trial means a clinical trial of a Product on sufficient numbers of patients that is designed to provide a preliminary determination of safety and efficacy of such Product in the target patient population over a range of doses and dose regimens.

  • Phase I Study means a study in humans which provides for the first introduction into humans of a product, conducted in healthy volunteers or patients to obtain information on product safety, tolerability, pharmacological activity or pharmacokinetics, as more fully defined in 21 C.F.R. § 312.21(a) (or the non-United States equivalent thereof).

  • Licensed Compounds means: (a) Research Program Active Compounds; (b) Novartis Active Compounds; (c) salts, hydrates, solvates, esters, metabolites, intermediates, stereoisomers and polymorphs of Research Program Active Compounds or Novartis Active Compounds; and (d) prodrugs of Research Program Active Compounds or Novartis Active Compounds (any of the foregoing, a “Licensed Compound”).

  • Phase II Trial means a clinical trial of a Licensed Product on patients, including possibly pharmacokinetic and dose ranging studies, the principal purposes of which are to make a preliminary determination that such Licensed Product is safe for its intended use and to obtain sufficient information about such Licensed Product’s efficacy to permit the design of further clinical trials, and generally consistent with 21 CFR §312.21(b), or its successor regulation, or the equivalent in any foreign country.

  • Phase II Clinical Trial means a controlled human clinical study that would satisfy the requirements of 21 CFR 312.21(b), conducted to study the effectiveness and establish the dose range of a Product for a particular Indication in patients with the disease or condition under study, including a Phase IIA Clinical Study or Phase IIB Clinical Study.

  • Backflow prevention device means a safety device used to prevent pollution or contamination of the water supply due to the reverse flow of water from the irrigation system.

  • Phase 2 Clinical Trial means a human clinical trial, for which the primary endpoints include a determination of dose ranges or an indication of efficacy in patients being studied as described in 21 C.F.R. §312.21(b), or an equivalent clinical trial in a country in the Territory other than the United States.

  • Cannabinoid extract means a substance obtained by separating cannabinoids from marijuana by: